2023
New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders
Jamshed F, Dashti F, Ouyang X, Mehal W, Banini B. New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders. World Journal Of Gastroenterology 2023, 29: 1824-1837. PMID: 37032732, PMCID: PMC10080697, DOI: 10.3748/wjg.v29.i12.1824.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient
Batisti J, Mehal W. Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. Current Transplantation Reports 2020, 7: 332-339. DOI: 10.1007/s40472-020-00303-0.Peer-Reviewed Original ResearchFatty liver diseaseLiver transplantNonalcoholic steatohepatitisLiver diseasePost liver transplant patientsReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseManagement of immunosuppressionManagement of NAFLDPost-transplant populationLiver transplant patientsPost-transplant periodExcess weight gainRecent FindingsRecent studiesGraft steatosisNAFLD interventionGraft fibrosisHepatic manifestationRecurrent diseaseTransplant patientsMetabolic syndromeMedical managementRecipient factorsInsulin resistanceLT populationS1016 Tolerance and Safety of Meal Replacement Program in Nonalcoholic Steatohepatitis With Fibrosis and Cirrhosis: A Case Series
Mankash M, Kelly M, Mehal W, Do A. S1016 Tolerance and Safety of Meal Replacement Program in Nonalcoholic Steatohepatitis With Fibrosis and Cirrhosis: A Case Series. The American Journal Of Gastroenterology 2020, 115: s518-s519. DOI: 10.14309/01.ajg.0000706112.69854.c1.Peer-Reviewed Original ResearchMeal replacement programNonalcoholic steatohepatitisCase seriesReplacement programCirrhosisSteatohepatitisFibrosis
2019
The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Yousaf M, Chaudhary F, Mehal W. The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Gastroenterology & Hepatology Open Access 2019, 10: 262-266. DOI: 10.15406/ghoa.2019.10.00392.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisFatty liver diseaseLiver diseaseSteatohepatitisDiseaseIncorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis
Do A, Kuszewski EJ, Langberg K, Mehal W. Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology 2019, 70: 1443-1456. PMID: 30991446, PMCID: PMC6783325, DOI: 10.1002/hep.30658.Peer-Reviewed Original ResearchConceptsTotal body weight lossWeight loss medicationsNonalcoholic steatohepatitisHepatology clinicStaging of NASHPartial histological responseBody weight lossHepatology practiceNASH histologyLiver histologyClinical profileLiver diseaseLiver triglyceridesNew medicationsClinical trialsHistological responseLifestyle changesPatientsMedicationsUncommonly resultsNatural historyClinical interventionsWeight lossSteatohepatitisHepatologists1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model
Mankash M, Kelly M, Dean J, Duffy A, Mehal W, Do A. 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model. The American Journal Of Gastroenterology 2019, 114: s599-s599. DOI: 10.14309/01.ajg.0000593756.22484.ae.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseWeight loss medicationsNonalcoholic steatohepatitisBariatric surgeryWeight lossClinical characteristicsLiver diseaseObesity managementEffective treatmentDisease programsAverage age 55Meal replacement therapySurgical weight lossWeight loss optionsAlanine aminotransferase levelsChronic liver diseaseFatty liver diseaseObstructive sleep apneaManagement of patientsCare of patientsLimited efficacy dataClinical care modelsLiver disease modelAverage weight lossHepatology clinic
2012
Sterile Inflammation in the Liver
Kubes P, Mehal WZ. Sterile Inflammation in the Liver. Gastroenterology 2012, 143: 1158-1172. PMID: 22982943, DOI: 10.1053/j.gastro.2012.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAdenosine TriphosphateCaspase 1Chemical and Drug Induced Liver InjuryChemotaxis, LeukocyteCytokinesFatty LiverFatty Liver, AlcoholicHepatitisHMGB1 ProteinHumansInflammasomesInterleukin-1betaNeutrophilsNon-alcoholic Fatty Liver DiseaseNucleic AcidsReceptors, Pattern RecognitionReperfusion InjurySignal TransductionUric AcidConceptsDamage-associated molecular patternsPattern recognition receptorsImmune cellsSterile inflammationRecognition receptorsCellular pattern recognition receptorsDrug-induced liver injuryEndogenous damage-associated molecular patternsSuch damage-associated molecular patternsMolecular patternsSite of injuryPathogen-associated molecular patternsProtease caspase-1Alcoholic steatohepatitisLiver injuryNonalcoholic steatohepatitisLiver diseaseProinflammatory cytokinesSpecific therapyInterleukin-1βLiver pathologyTissue injuryImmune responseTherapeutic targetActivate receptors